Thuy Van Lam van

Thuy Van Lam van

Auto-generated profile, based on publicly available information

Thuy Van Lam van

Institute of Pharmaceutical Chemistry, Philipps-University, Marburg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
DBDorothea Bestle
Dorothea Bestle
MHMiriam Ruth Heindl
Miriam Ruth Heindl
HLHannah Limburg
Hannah Limburg
TVThuy Van Lam van
Thuy Van Lam van
OPOliver Pilgram
Oliver Pilgram
EBEva Böttcher-Friebertshäuser
Eva Böttcher-Friebertshäuser
The novel emerged SARS-CoV-2 has rapidly spread around the world causing acute infection of the respiratory tract (COVID-19) that can result in severe disease and lethality. For SARS-CoV-2 to enter cells, its surface glycoprotein spike (S) must be cleaved at two different sites by host cell proteases, which therefore represent potential drug targets. In the present study, we show that S can be cleaved by the proprotein convertase furin at the S1/S2 site and the transmembrane serine protease 2 (TMPRSS2) at the S2′ site. We demonstrate that TMPRSS2 is essential for activation of SARS-CoV-2 S in Calu-3 human airway epithelial cells through antisense-mediated knockdown of TMPRSS2 expression. Furthermore, SARS-CoV-2 replication was also strongly inhibited by the synthetic furin inhibitor MI-1851 in human airway cells. In contrast, inhibition of endosomal cathepsins by E64d did not affect virus replication. Combining various TMPRSS2 inhibitors with furin inhibitor MI-1851 produced more potent antiviral activity against SARS-CoV-2 than an equimolar amount of any single serine protease inhibitor. Therefore, this approach has considerable therapeutic potential for treatment of COVID-19.